Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non–Small-Cell Lung Cancer: Long-Term Results of a Multi-Institutional, Phase II, Randomized StudyDaniel R. Gomez, John V. Heymach, Chad Tang et al.|Journal of Clinical Oncology|2019Cited by 1.3k
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 studyDaniel R. Gomez, John V. Heymach, George R. Blumenschein et al.|The Lancet Oncology|2016Cited by 1.1k
Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilitiesCarl M. Gay, Lauren A. Byers, C. Allison Stewart et al.|Cancer Cell|2021Cited by 930
Molecular Mechanisms and Future Implications of VEGF/VEGFR in Cancer TherapySonia Patel, John V. Heymach|Clinical Cancer Research|2022Cited by 434
Circulating tumor DNA dynamics predict benefit from consolidation immunotherapy in locally advanced non-small-cell lung cancerEverett J. Moding, Maximilian Diehn, Yufei Liu et al.|Nature Cancer|2020Cited by 369